Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
failed trials
Biotech
Amgen halts gastric cancer trial after subpar efficacy analysis
Fortitude-102 was testing bemarituzumab, a monoclonal antibody, in combination with chemotherapy and BMS’ Opdivo in 515 patients.
Darren Incorvaia
Nov 5, 2025 4:35am
Harmony halts genetic disease program after phase 3 failure
Nov 4, 2025 12:45pm
Sanofi drops toddler RSV vaccine after ph. 3 heads for failure
Oct 24, 2025 7:00am
Moderna scraps congenital virus program after vax fails ph. 3
Oct 22, 2025 5:15pm
Alector halves staff after GSK-partnered antibody fails in ph. 3
Oct 22, 2025 11:23am
Neuphoria nixes social anxiety program after phase 3 flop
Oct 21, 2025 10:44am
